Research Paper Volume 12, Issue 7 pp 5792—5811

Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML

Figure 6. Overall survival and disease free survival of the AML patients according to risk groups (favorable and intermediate vs poor) within age arms (60-66 vs 67-74 vs ≥ 75 years). (A) Overall survival of the AML patients aged 60-66 years according to risk groups. (B) Disease free survival of the AML patients aged 60-66 years according to risk groups. (C) Overall survival of the AML patients aged 67-74 years according to risk groups. (D) Disease free survival of the AML patients aged 67-74 years according to risk groups. (E) Overall survival of the AML patients aged ≥75 years according to risk groups. (F) Disease free survival of the AML patients aged ≥75 years according to risk groups.